NEW YORK, NY--The Irving Institute for Clinical and Translational Research has been awarded a seven-year, $75 million Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).
As a cornerstone of clinical and translational research across Columbia University Irving Medical Center (CUIMC), the Irving Institute drives translational science by supporting and advancing the full biomedical research enterprise of the University. The Irving Institute’s infrastructure, education, services, and strategic support enable CUIMC investigators to move discoveries from bench to bedside more efficiently and with greater impact.
The grant will advance clinical and translational research by:
“This renewal enhances Columbia’s capabilities to accelerate translation of basic discoveries and clinical trials into patient care,” said Muredach Reilly, MBBCh, MSCE, director of the Irving Institute and vice dean for clinical and translational research at Columbia University Vagelos College of Physicians and Surgeons (VP&S). “Over the next seven years, we are especially focused on building the scientific tools and community partnerships needed to improve human health across the lifespan for the patients and communities in Upper Manhattan and our nation.”
This year also marks the 20th anniversary of the Irving Institute. Founded in 2006, the Irving Institute was among the first 12 academic medical centers in the United States to receive CTSA grant funding. This is the fifth consecutive CTSA grant awarded to Columbia since 2006—with previous awards of $54 million in 2006, $38.9 million in 2011, $58.4 million in 2016, and $61.7 million in 2021—bringing total NIH CTSA Program funding to $288 million.
“The Irving Institute is instrumental in driving groundbreaking healthcare discoveries and training the next generation of scientific leaders,” said James McKiernan, MD, interim dean of the faculties of health sciences at VP&S and executive vice president for health and biomedical sciences at Columbia University. “Sustaining this work for over two decades, and earning a fifth consecutive CTSA grant, reflects the caliber of the people and partnerships Columbia has built around translational science.”
Irving Institute Leadership Quotes:
"This grant helps us to partner closely with clinical and community stakeholders to ensure evidence-based interventions reach the patients who need them most." — Rachel Shelton, ScD, MPH , co-director of the Irving Institute
"Future scientific progress depends on training investigators who can think across disciplines, adapt to rapidly evolving technologies, and lead collaborative discovery." — Daichi Shimbo, MD, co-director of the Irving Institute
"This grant helps us develop better methods for tracking exactly which scientific programs are working, and just as importantly, which ones aren't, so we can make our research more efficient and impactful.— Harold Pincus, MD, co-director of the Irving Institute
About the NIH CTSA Program
The Clinical and Translational Science Award (CTSA) Program is led by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health. The CTSA Program supports a national network of medical research institutions that work together to improve the translational research process and accelerate research discoveries into health solutions.
###
Columbia University Irving Medical Center (CUIMC) is a clinical, research, and educational campus located in New York City. Founded in 1928, CUIMC was one of the first academic medical centers established in the United States of America. CUIMC is home to four professional colleges and schools that provide global leadership in scientific research, health and medical education, and patient care including the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing. For more information, please visit cuimc.columbia.edu .